# ROBO2

Source: https://onco.cc/targets/robo2/  
OnCo record `robo2` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

ROBO2 (Roundabout homolog 2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Colorectal cancer, Prostate cancer, Renal cell carcinoma and 5 more.

## Summary

Receptor for SLIT2, and probably SLIT1, which are thought to act as molecular guidance cue in cellular migration, including axonal navigation at the ventral midline of the neural tube and projection of axons to different regions during neuronal development.

IntOGen calls it a driver in 16 cohorts (8 activating, 8 loss-of-function), covering Chromophobe Renal Cell Carcinoma, Chronic Lymphocytic Leukaemia/Small Lymphocytic Lymphoma, Colon Adenocarcinoma, Colorectal Adenocarcinoma, Oesophagogastric Adenocarcinoma, Oesophageal Adenocarcinoma and others.

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: roundabout guidance receptor 2; Roundabout homolog 2; KIAA1568
- Tags: cancer-genes-wave
- Symbol: ROBO2
- Class: tumor-suppressor
- Biology: Receptor for SLIT2, and probably SLIT1, which are thought to act as molecular guidance cue in cellular migration, including axonal navigation at the ventral midline of the neural tube and projection of axons to different regions during neuronal development. Location: Membrane (UniProt). Locus 3p12.3 (HGNC).
- Where found: Colorectal cancer: IntOGen driver in 5 cohorts (COAD, COADREAD); Prostate cancer: IntOGen driver in 2 cohorts (PRAD); Renal cell carcinoma: IntOGen driver in 1 cohort (CHRCC); Gastric & gastro-oesophageal junction cancer: IntOGen driver in 1 cohort (EGC); Oesophageal cancer: IntOGen driver in 1 cohort (ESCA); Hepatocellular carcinoma: IntOGen driver in 1 cohort (HCC)

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 8 cohorts; IntOGen calls it a loss-of-function (LoF) driver in 8 cohorts; UniProt disease notes describe a translocation or gene fusion involving the gene. Evidence tier "cohort-driver" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.

## Sources

- HGNC HGNC:10250: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10250
- UniProt Q9HCK4: https://www.uniprot.org/uniprotkb/Q9HCK4/entry
- NCBI Gene 6092: https://www.ncbi.nlm.nih.gov/gene/6092
- Ensembl ENSG00000185008: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000185008

## Connected records

- collections: [IntOGen](https://onco.cc/collections/intogen/)
- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/), [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/), [Melanoma](https://onco.cc/cancers/melanoma/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/), [Oesophageal cancer](https://onco.cc/cancers/esophageal/), [Prostate cancer](https://onco.cc/cancers/prostate/), [Renal cell carcinoma](https://onco.cc/cancers/rcc/)

---
JSON: https://onco.cc/api/v1/entities/robo2.json